Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D1.349 - Early Diagnosis of WHIM Syndrome in Infancy: A Case with a De Novo CXCR4 Mutation
D1.348 - Retrospective Evaluation of Laboratory and Clinical Characteristics of Pediatric Patients Diagnosed with IgG Subclass Deficiency and Receiving Intravenous Immunoglobulin Replacement Therapy
D1.350 - Selective IgA deficiency and its association with allergic and autoimmune diseases
D1.351 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular associations
D1.353 - A Rare Cause of Recurrent Infections: SIFD Syndrome
D1.354 - Possible Association of a MYOF Loss-of-Function Variant With Recurrent Angioedema: Overlap Between Chronic Spontaneous Urticaria and Normal-C1 Hereditary Angioedema? A Case Report
D1.355 - Familial Recurrent Angioedema with Normal C1-Inhibitor: A Clinical Case Series Suggestive of HAE with Normal C1-INH
D1.356 - Atypical association of anti-EJ and anti-RNA polymerase III antibodies in a patient referred for interstitial lung disease
D1.357 - Atypical case of common variable immune deficiency with granulomatous lymphocytic interstitial lung disease
D1.363 - Long-Acting Prophylactic Injection BW-20805: Remarkable and Sustained HAE Attack Reduction — Updated Analysis from an Ongoing Phase 2 Study
D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
D1.108 - Optimization of phenotyping in severe T2-bronchial asthma
D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study
D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study
D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research
D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download